Rhumbline Advisers Sells 1,195 Shares of Mineralys Therapeutics, Inc. $MLYS

Rhumbline Advisers reduced its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 2.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 39,361 shares of the company’s stock after selling 1,195 shares during the quarter. Rhumbline Advisers owned approximately 0.06% of Mineralys Therapeutics worth $625,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Wellington Management Group LLP raised its holdings in Mineralys Therapeutics by 32.8% during the first quarter. Wellington Management Group LLP now owns 121,557 shares of the company’s stock valued at $1,930,000 after acquiring an additional 30,028 shares during the period. GAMMA Investing LLC raised its holdings in Mineralys Therapeutics by 9,602.2% during the first quarter. GAMMA Investing LLC now owns 8,829 shares of the company’s stock valued at $140,000 after acquiring an additional 8,738 shares during the period. BNP Paribas Financial Markets bought a new stake in Mineralys Therapeutics during the fourth quarter valued at about $48,000. Bank of America Corp DE raised its holdings in Mineralys Therapeutics by 12.0% during the fourth quarter. Bank of America Corp DE now owns 107,703 shares of the company’s stock valued at $1,326,000 after acquiring an additional 11,549 shares during the period. Finally, ProShare Advisors LLC bought a new stake in Mineralys Therapeutics during the fourth quarter valued at about $128,000. 84.46% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Mineralys Therapeutics news, CEO Jon Congleton sold 15,884 shares of the company’s stock in a transaction on Friday, July 11th. The shares were sold at an average price of $14.51, for a total value of $230,476.84. Following the sale, the chief executive officer directly owned 846,405 shares of the company’s stock, valued at approximately $12,281,336.55. This represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Malcom Rodman sold 11,367 shares of the company’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $36.00, for a total transaction of $409,212.00. Following the completion of the sale, the insider directly owned 81,524 shares in the company, valued at approximately $2,934,864. The trade was a 12.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 134,418 shares of company stock valued at $2,185,474 in the last 90 days. 33.24% of the stock is currently owned by insiders.

Mineralys Therapeutics Stock Down 1.2%

Shares of NASDAQ:MLYS opened at $38.78 on Tuesday. The company has a market capitalization of $2.57 billion, a price-to-earnings ratio of -10.89 and a beta of -0.29. Mineralys Therapeutics, Inc. has a 52 week low of $8.24 and a 52 week high of $40.33. The firm has a 50 day moving average of $20.78 and a 200 day moving average of $16.73.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.12. On average, sell-side analysts expect that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. The Goldman Sachs Group raised their price target on Mineralys Therapeutics from $32.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, September 9th. Jefferies Financial Group raised their price target on Mineralys Therapeutics from $15.00 to $26.00 and gave the company a “hold” rating in a report on Wednesday, September 3rd. Bank of America raised their price target on Mineralys Therapeutics from $38.00 to $43.00 and gave the company a “buy” rating in a report on Thursday, August 28th. Wells Fargo & Company raised their price objective on Mineralys Therapeutics from $26.00 to $50.00 and gave the company an “overweight” rating in a research report on Thursday, September 11th. Finally, Wall Street Zen upgraded Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 22nd. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.50.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.